Precision Biosensor, Inc. (KOSDAQ:335810)

Market Cap	47.96B +45.7%
Revenue (ttm)	19.74B +8.4%
Net Income	-7.88B
EPS	-678.25
Shares Out	21.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,037
Average Volume	25,211
Open	2,165.00
Previous Close	2,155.00
Day's Range	2,150.00 - 2,245.00
52-Week Range	2,100.00 - 4,500.00
Beta	0.61
RSI	27.53
Earnings Date	Mar 18, 2026

About Precision Biosensor

Precision Biosensor, Inc. engages in the development, production, and sale of immune diagnostic kits in South Korea. It offers Exdia TRF Plus, an immunodiagnosis POCT platform; and Exdia PT10 and Exdia PT10S, a clinical chemistry POCT platform. The company was founded in 2009 and is headquartered in Daejeon, South Korea.

• Industry: Measuring and Controlling Devices, not elsewhere classified
• Founded: 2009
• Employees: 98
• Stock Exchange: KOSDAQ
• Ticker Symbol: 335810

Financial Performance

In 2024, Precision Biosensor's revenue was 19.13 billion, a decrease of -6.16% compared to the previous year's 20.39 billion. Losses were -7.31 billion, 62.7% more than in 2023.